{"id":"NCT03512197","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)","officialTitle":"A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-20","primaryCompletion":"2021-02-12","completion":"2021-02-12","firstPosted":"2018-04-30","resultsPosted":"2023-06-18","lastUpdate":"2023-08-21"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia (AML)"],"interventions":[{"type":"DRUG","name":"Midostaurin","otherNames":["PKC412"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Chemotherapy","otherNames":[]}],"arms":[{"label":"Midostaurin + chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR\\<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off).\n\nThis study evaluated the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR\\<0.05) AML.","primaryOutcome":{"measure":"Event Free Survival (EFS)","timeFrame":"From date of Randomization up to approx. 30 months","effectByArm":[{"arm":"Midostaurin + Chemotherapy","deltaMin":5.98,"sd":null},{"arm":"Placebo + Chemotherapy","deltaMin":5.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":133,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Czechia","France","Germany","Israel","Italy","Japan","Norway","Poland","Portugal","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1104"]},"adverseEventsSummary":{"seriousAny":{"events":95,"n":245},"commonTop":["Pyrexia","Nausea","Diarrhoea","Febrile neutropenia","Hypokalaemia"]}}